1[1]Ohkubo Y, Kishikawa H,Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective-year study. Diabetes Res Clin Pract, 1995,28(3): 103
2[2]UK prospective diabetes study group. Intensive blood glucose con
3[3]trol with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet, 1998,352(7) :837
6[6]Owens DR. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med, 1998,15 ( 4 ): 28
二级参考文献15
11，Fuhlendorff J,Rorsman P,Kofod H et al.Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinet processes.Diabetes,1998;47(3):345
22，Owens DR.repaglinide-prandial glucose regulator:a new class of oral antidiabetic drugs.Diabet Med,1998;15suppl(4):S28
33，John R,White Jr,Pharm D.The pharmacological reduction of blood glucose in patients with type 2 diabetes melitus.Clinical Diabetes,1998;16:2
44 Polonsky KS,Sturis J,Bell CI.Seminars in Medicine of the Beth Israel Hospital,Boston.Non-insulin-dependent diabetes melitus-a genetically programmed failure of the beta cell to compensate for insulin resistance.N Engl J Med,1996;334(12):777
55，P J Lefebvre,Scheen AJ.The postprandial state risk of cardiovascular disease.Diabet Med,1998;15(Suppl 4):S63
66，Goldberg,Einhorn D,Lucas CP,et al.A randomized placebocontrolled trial of repaglinide in the teatment of type 2 diabetes.Diabetes Care,1998;21(11):1897
77，Landgraf R,Bilo HJ.A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.1999;55(3):165
88，Wolffenbuttel BH,LandgrafR.A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes.Dutch and German repaglinide Study Group Diabetes Care,1999;22(3):463
